These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 982929)

  • 41. Pathogenic significance and prognosis of rheumatic nodules.
    Dimitriu CG; Dimitriu M
    Rum Med Rev; 1965; 19(3):8-13. PubMed ID: 5842881
    [No Abstract]   [Full Text] [Related]  

  • 42. Slow acting antirheumatic drugs in rheumatoid arthritis.
    Gow PJ
    N Z Med J; 1993 Mar; 106(951):85-7. PubMed ID: 8474708
    [No Abstract]   [Full Text] [Related]  

  • 43. [Morphological principles of rheumatic diseases].
    Jansen HH
    Med Welt; 1972 Nov; 23(45):1621-6. PubMed ID: 4539135
    [No Abstract]   [Full Text] [Related]  

  • 44. [Mechanism of action and indications of coacervated aspirin].
    Simplicio F; Scagliusi P; Sozio N
    Reumatismo; 1972; 24(3):183-99. PubMed ID: 4549697
    [No Abstract]   [Full Text] [Related]  

  • 45. [20 years of corticoid therapy in rheumatic diseases].
    Dimitriu CG; Nestor R; Dimitriu R
    Med Interna (Bucur); 1969 Sep; 21(9):1027-35. PubMed ID: 5378235
    [No Abstract]   [Full Text] [Related]  

  • 46. Mechanisms of action of disease modifying antirheumatic drugs.
    Harth M
    J Rheumatol Suppl; 1992 Jan; 32():100-3. PubMed ID: 1613728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Drug therapy of rheumatoid arthritis. Recommendations to specialists and general practitioners].
    Glennås A; Ostensen M
    Tidsskr Nor Laegeforen; 1994 Jan; 114(2):185-6. PubMed ID: 8122200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical evaluation of the use in arthrosis of a drug with antirheumatic and anti-inflammatory action].
    Zanasi R; Volonteri G; Castaldi D
    Minerva Med; 1971 Jan; 62(3):174-8. PubMed ID: 4250776
    [No Abstract]   [Full Text] [Related]  

  • 49. [When do we use which drugs? Procedures for the treatment of rheumatoid arthritis].
    Bolten WW
    Pharm Unserer Zeit; 2003; 32(5):405-12. PubMed ID: 14526461
    [No Abstract]   [Full Text] [Related]  

  • 50. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee.
    Tugwell P; Boers M
    J Rheumatol; 1993 Mar; 20(3):555-6. PubMed ID: 8478872
    [No Abstract]   [Full Text] [Related]  

  • 51. [Ant-inflammatory or antirheumatic agents? The pharmacological activity and therapeutic effectiveness of non-steroidal anti-inflammatory drugs: comparative study. I].
    Mariani L; Baratelli M
    Clin Ter; 1980 Jan; 92(2):105-26. PubMed ID: 6966996
    [No Abstract]   [Full Text] [Related]  

  • 52. Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.
    Emery P; Luqmani R; Gordon C
    Br J Clin Pract; 1994; 48(2):82-6. PubMed ID: 7912952
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New classification of antirheumatic drugs. The evolution of a concept.
    Edmonds JP; Scott DL; Furst DE; Paulus HE
    J Rheumatol; 1993 Mar; 20(3):585-7. PubMed ID: 8478880
    [No Abstract]   [Full Text] [Related]  

  • 54. [The drug spectrum in rheumatoid arthritis therapy].
    Fellinger K
    Acta Med Austriaca; 1975; 2(4):105-10. PubMed ID: 1224926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pharmacologic therapy of rheumatoid arthritis with delayed-action anti-rheumatic drugs].
    Saal JG
    Internist (Berl); 1993 Jan; 34(1):9-17. PubMed ID: 8440581
    [No Abstract]   [Full Text] [Related]  

  • 56. [Our 1st experiences with tanderil in the treatment of rheumatic diseases].
    Vitaus M
    Reumatizam; 1966; 13(6):216-7. PubMed ID: 5973924
    [No Abstract]   [Full Text] [Related]  

  • 57. What is a disease modifying antirheumatic drug?
    Hepburn B
    J Rheumatol Suppl; 1988 Sep; 16():40-2. PubMed ID: 2903926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance.
    Butoescu N; Jordan O; Doelker E
    Eur J Pharm Biopharm; 2009 Oct; 73(2):205-18. PubMed ID: 19545624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Combination therapy of slow-acting antirheumatic drugs].
    Nobunaga M
    Ryumachi; 1994 Feb; 34(1):88-98. PubMed ID: 8146734
    [No Abstract]   [Full Text] [Related]  

  • 60. [Inflammatory rheumatism and fundamentals of its drug therapy].
    Borkenstein E
    Wien Med Wochenschr; 1971 May; 121(22):449-52. PubMed ID: 5314609
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.